Hildegund C.J. Ertl

The Wistar Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

67h-index18.4kcitations302works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(114), Immunotherapy and Immune Responses(66), Rabies epidemiology and control(60), CAR-T cell therapy research(50), Immune Cell Function and Interaction(42)

Publications302 total

Metabolism of tumor infiltrating T cells
Frontiers in Immunology·2026Open Access
Rabies glycoprotein engineering for improved stability and expression
Vaccine·2025Open Access
Human and animal vaccines
Elsevier eBooks·2025
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses
JCI Insight·2024· 6 citedOpen Access
LBP-018 Promising first-in-human, first-in-class, Phase 1B immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cure
Journal of Hepatology·2024· 2 cited
Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma
Molecular Therapy — Oncolytics·2023· 11 citedOpen Access
454 Checkpoint modification of early T cell activation provides enhanced anti-tumor activity and survival benefits in a fast-growing preclinical tumor challenge model
Regular and Young Investigator Award Abstracts·2023Open Access
Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors
Human Gene Therapy·2023· 8 cited
Peptides as Molecular Probes of Immune Responses
2023
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for <i>Human Gene Therapy</i>
Human Gene Therapy·2023
Intrahepatic CD8+ T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse model
Journal of Hepatology·2023
Supplemental Figure 2 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 4 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Data from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 4 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 2 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 1 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 1 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 6 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
Supplemental Figure 6 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy
2023Open Access
page 1 of 16Next →

Frequent Co-authors

James M. Wilson(14), Zhiquan Xiang(9), Katherine A. High(7), Wynetta Giles‐Davis(7), Guangping Gao(7), Zhi Quan Xiang(5), William H. Wunner(5), Bernhard Dietzschold(5), Arturo Reyes‐Sandoval(5), Nia Tatsis(4), Yiping Yang(4), Marcio O. Lasaro(4), Michael R. Betts(4), Denise E. Sabatino(3), Ying Zhang(3), Raj K. Kurupati(3), Jun Cheng(3), Roland W. Herzog(3), Julie C. Fitzgerald(3), Scott E. Hensley(3)